Repligen
RGEN
#2857
Rank
A$8.22 B
Marketcap
A$145.81
Share price
1.29%
Change (1 day)
-25.41%
Change (1 year)
Categories

P/E ratio for Repligen (RGEN)

P/E ratio as of May 2026 (TTM): 113

According to Repligen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 113.261. At the end of 2025 the company had a P/E ratio of 188.

P/E ratio history for Repligen from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025188-166.73%
2024-282-217.73%
2023240375.76%
202250.4-55.48%
2021113-32.67%
2020168-18.22%
201920648.11%
2018139179.26%
201749.7-43.56%
201688.1-9.73%
201597.623.17%
201479.2184.52%
201327.8103.9%
201213.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Pfizer
PFE
19.3-82.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
24.3-78.58%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
34.9-69.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
16.1-85.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
-0.2900-100.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
3.26-97.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
23.4-79.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
62.6-44.75%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
35.5-68.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
-50.8-144.87%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.